Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. (CGEM) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CGEM · as of Sep 30, 2025
Ownership Breakdown
146
Institutional Holders
$362.47M
Total Inst. Value
▼ $108.96M vs Q2
61.46M
Shares Outstanding
freeFloat 72.04%
61.08M
13F Shares Held
▼ 1.53M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CGEM largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BIOIMPACT CAPITAL LLC biological products, (no diagnostic substances) | 7.65M | 12.96% | 12.96% | $45.35B | Nov 14, 2025 | — held |
LYNX1 CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 5.77M | 9.77% | 9.77% | $34.19B | Nov 13, 2025 | ▲ 1.37M |
BVF INC/IL biological products, (no diagnostic substances) | 5.75M | 9.74% | 9.74% | $34.10B | Nov 14, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 4.17M | 7.07% | 7.07% | $24.73B | Nov 12, 2025 | ▼ 48.0K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.94M | 4.99% | 4.99% | $17.45B | Nov 7, 2025 | ▼ 76.8K |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) biological products, (no diagnostic substances) | 2.93M | 4.96% | 4.96% | $17.36B | Nov 14, 2025 | ▼ 928.5K |
BLUE OWL CAPITAL HOLDINGS LP biological products, (no diagnostic substances) | 2.51M | 4.25% | 4.25% | $14.89B | Nov 12, 2025 | ▲ 125.0K |
KYNAM CAPITAL MANAGEMENT, LP biological products, (no diagnostic substances) | 2.30M | 3.90% | 3.90% | $13.65B | Nov 14, 2025 | ▲ 206.2K |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 1.98M | 3.36% | 3.36% | $11.77B | Nov 14, 2025 | ▼ 629.3K |
ORBIMED ADVISORS LLC biological products, (no diagnostic substances) | 1.92M | 3.26% | 3.26% | $11.41B | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
22
Increased
+3.60M shares3
New Positions
first time holders15
Decreased
−3.26M shares0
Sold Out
fully exitedNet shares change (top 50)
+343.0K
+3.60M / −3.26M
Net new holders
+10
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CGEM insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
3
Sell transactions
0.33
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Michaelson Jennifer Chief Scientific Officer | May 5, 2026 | Sale | 7,800 | $14.60 | $113.9K | 167.0K | Form 4 ↗ |
Michaelson Jennifer Chief Scientific Officer | May 5, 2026 | Sale | 200 | $15.58 | $3.1K | 166.8K | Form 4 ↗ |
Michaelson Jennifer Chief Scientific Officer | Mar 5, 2026 | Sale | 8,000 | $15.68 | $125.4K | 170.8K | Form 4 ↗ |
Michaelson Jennifer Chief Scientific Officer | Feb 25, 2026 | Sale | 1,780 | $14.14 | $25.2K | 174.8K | Form 4 ↗ |
Michaelson Jennifer Chief Scientific Officer | Feb 23, 2026 | Sale | 1,752 | $13.99 | $24.5K | 180.2K | Form 4 ↗ |
Michaelson Jennifer Chief Scientific Officer | Feb 24, 2026 | Sale | 3,601 | $14.47 | $52.1K | 176.6K | Form 4 ↗ |
AHMED NADIM President and CEO | Feb 24, 2026 | Sale | 13,515 | $14.47 | $195.6K | 390.8K | Form 4 ↗ |
Jones Jeffrey Alan Chief Medical Officer | Feb 24, 2026 | Sale | 4,582 | $14.47 | $66.3K | 160.0K | Form 4 ↗ |
SUMER JACQUELYN L Chief Legal Officer | Feb 24, 2026 | Sale | 3,601 | $14.47 | $52.1K | 128.1K | Form 4 ↗ |
Jones Jeffrey Alan Chief Medical Officer | Feb 20, 2026 | Sale | 4,982 | $13.62 | $67.9K | 164.6K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Cullinan Therapeutics, Inc. (CGEM) is primarily owned by institutional investors, who hold approximately 99.4% of total shares outstanding. Company insiders own approximately 27.96%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Cullinan Therapeutics, Inc. is BIOIMPACT CAPITAL LLC, holding approximately 7.65 million shares — equal to 12.96% of outstanding shares — as of September 30, 2025.
A total of 146 institutional investors currently hold CGEM stock, with a combined institutional value of approximately $362,471,981 as of the most recent 13F filing period.
Frequently asked questions
CGEM ownershipCullinan Therapeutics, Inc. (CGEM) is primarily owned by institutional investors, who hold approximately 99.4% of shares. The largest shareholder is BIOIMPACT CAPITAL LLC with a 12.96% stake. Company insiders hold 27.96%. Data sourced from SEC Form 13F as of September 30, 2025.